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Immunology and Microbiology
Efficacy of Intravitreal Administrations of Linezolid in an
Experimental Model of S. aureus–Related Endophthalmitis
Maher Saleh,1,2 Sophie Lefe`vre,1 Niyazi Acar,3 Tristan Bourcier,2 Luc Marcellin,4 Gilles Pre´vost,1
Audrey Subilia,2 David Gaucher,2 and Franc¸ois Jehl1
PURPOSE. To evaluate the efficacy of intravitreal administration
of linezolid (LZD) in a rabbit model of Staphylococcus aureus
endophthalmitis.
METHODS. Of 40 rabbits studied, 36 of them received 102
colony-forming units (CFU) of S. aureus in their right eye
before being randomly assigned to the following groups: four
groups of 8 animals received 24 hours after the bacterial
inoculation, 1, 10, 30 mg of LZD (LZD 1, LZD 10, and LZD 30)
or 1 mg of vancomycin (V1), respectively. Four other animals
had a sham injection in their infected eye. The 4 remaining
animals were used as negative controls. Clinical, bacterial, and
histologic assessments were conducted at different endpoints.
Animals were euthanized at day 8. The safety profile of
intravitreal LZD was assessed by electroretinography in 5 more
animals by comparing the recordings in eyes injected with 30
mg of LZD and contralateral control eyes injected with a
solution of sterile saline water.
RESULTS. At day 5, the mean inflammatory clinical scores of
Nussenblatt were 7.0 6 1.0, 3.6 6 0.7, and 3.1 6 0.8, in the
LZD 1, LZD 10, and LZD 30 groups and 3.4 6 1.7 and 7.5 6 0
in the V1 and BSSþ groups, respectively (P < 0.05, ANOVA).
The corresponding mean bacterial counts in the vitreous (log
10 CFU/mL) were 6.2 6 6.5, 3.5 6 3.8, 0, 3.8 6 4.2, and 7.8 6
4.9, respectively (P < 0.05, ANOVA). A 30 mg dose of LZD
sterilized all the eyes at day 5 and displayed the lowest (best)
histologic score (1.5 6 0.6). Residual LZD concentrations 24
hours after the administration were between 0.1 and 7.2 mg/L
LZD 30 group. The half-time of linezolid in the vitreous was 2
hours. There were no differences in the electroretinogram
recordings between control eyes and eyes injected with 30 mg
of linezolid at days 1 and 14 after the intravitreal injection.
CONCLUSIONS. This is the first evidence of the effectiveness of
linezolid for the treatment of experimental staphylococcal
endophthalmitis. High ocular concentrations of LZD were
needed to obtain a satisfactory bactericidal effect. Linezolid
displayed a concentration-dependent killing activity in the eye.
Such doses of intravitreal linezolid appeared to be safe for the
retinal function. (Invest Ophthalmol Vis Sci. 2012;53:4832–
4841) DOI:10.1167/iovs.11-8417
Despite appropriate antibiotic treatment, bacterial endoph-thalmitis still frequently leads to permanent visual loss in
the affected eyes.
The leading causative organisms are cocci Gram-positive,
with a predominance of coagulase-negative Staphylococcus
followed by Staphylococcus aureus and streptococcal spe-
cies.1–3 Because the intravitreal route provides immediate and
high local concentrations of the drugs,4 intravitreal injection of
antibiotics (i.e., vancomycin and/or ceftazidim) is the standard
therapy for Gram-positive–related endophthalmitis. However,
the increasing antibiotic resistance among methicillin-resistant
S. aureus observed in some severe infections5 has also been
reported to occur in endophthalmitis isolates.6 After the
emergence of vancomycin-resistant enterococci in the 1980s,
significant concern existed with regard to the potential for
large outbreaks of vancomycin-resistant S. aureus (VRSA) due
to the acquisition of the vanA gene from enterococci by
horizontal gene transfer.7 The vanA gene, encoded within a
transposon, Tn1546, located on a plasmid, confers vanA-type
vancomycin resistance in enterococci.8 However, to date, only
a few cases of VRSA due to the acquisition of the vanA gene
have been reported. The phenomenon of vancomycin hetero-
resistance in S. aureus (hVISA) has been reported to occur
more frequently, although the best method to detect hVISA
strains and their clinical significance are ill-defined.7 They have
been detected globally and in many cases are associated with
glycopeptide treatment failure. Sequential point mutations in
key global regulatory genes seem to contribute to such VISA
phenotypes.
In the case of endophthalmitis, even if the responsible
Gram-positive bacteria are still susceptible to vancomycin,9
sporadic cases of vancomycin resistance are emerging (en-
dophthalmitis caused by vancomycin-resistant Enterococcus
[VRE]10) and an elevation of the vancomycin. The minimal
inhibitory concentration (MIC) within the susceptible range
has been observed in coagulase-negative staphylococci isolates
recovered from endophthalmitis (Pathengay A, et al. IOVS
2011;52:ARVO E-Abstract 2972). Such a development in
bacterial resistance would be an issue of major concern
considering that few antibiotics given by the intravitreal route
provide both satisfactory antibacterial efficacy and good
tolerance.
An antibiotic targeting Gram-positive bacteria and active
against the agents resistant to other antibiotics would be of
some interest in the management of endophthalmitis. The
oxazolidinones are a recent class of synthetic antibacterial
agents, the first compound of which to be commercialized was
linezolid (LZD). In vitro and in vivo studies have demonstrated
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that linezolid has significant antimicrobial activity against
Streptococcus pneumoniae, reported to be responsible for
severe endophthalmitis11 and against multiresistant Gram-
positive pathogens such as methicillin-resistant S. aureus,12
and vancomycin-resistant Enterococcus (VRE).13 In addition,
linezolid blocks the formation of the 70S subunit, which
inhibits the initiation of translation. This specific mechanism of
action reduces the risk of cross-resistance with other
antimicrobial agents.
Pharmacokinetics of oral,14–16 intravenous,17 and topical18
linezolid have been investigated in human and animals’
noninflamed eyes. Results have demonstrated an interesting
ocular penetration in both the anterior segment of the eye, and
into the vitreous body. Therefore, it has been suggested that
linezolid could play a role in the treatment of Gram-positive-
related endophthalmitis.14–16
However, there are no data available on the efficacy of
linezolid administered in infected eyes. In this study, we
compared the efficacy of intravitreal administrations of line-
zolid versus vancomycin, the treatment of reference in
staphylococcal endophthalmitis, in an experimental model of
S. aureus endophthalmitis.
METHODS
In Vivo Experimental Model of S. aureus
Endophthalmitis
Forty female New Zealand albino rabbits, weighing between 3 and 4
kg, were obtained from the Animal Experimentation Service of the
University of Strasbourg (Agreement number A-67-482-34). They were
maintained on water and standard laboratory chow without restriction
throughout the study in rooms with a controlled temperature (218C)
and light cycle (12/24 hours). The animals were obtained and cared for
in accordance with the recommendations of the ARVO guidelines for
the Use of Animals in Ophthalmic and Visual Research (ARVO).
Strain and Bacterial Preparation
A strain of methicillin-resistant S. aureus was isolated from a corneal
sample of a patient with a corneal keratitis and its antibiotic
susceptibility and toxin profiles were determined. Classification and
identification were performed using a mass spectrometry system
(Microflex MALDI-BioTyper system; Bruker Daltonics, Bremen, Ger-
many). Isolate was tested for susceptibility to oxacillin, vancomycin,
and linezolid (VITEK 2 system; bioMe´rieux Clinical Diagnostics, Marcy
l’Etoile, France). Susceptibility breakpoints and interpretive criteria
were used from the 2011 recommendations of the Antibiogram
Committee of the French Microbiology Society guidelines. Antimicro-
bial resistance testing was carried out to determine the vancomycin
and linezolid MICs (Etest; bioMe´rieux Clinical Diagnostics) (Table 1).
The mass spectrum of the S. aureus strain was similar to the S. aureus
American Type Culture Collection (ATCC, Manassas, VA) 29737
reference strain, with a log score of 2.332. The isolate was cultured
for 18 hours on a 5% (wt/vol) sheep blood agar plate, then colonies
were harvested and diluted in 0.9% of NaCl (wt/vol) to achieve the
desired bacterial count (i.e., 102 colony-forming units [CFU] per 0.1
mL). Counts were verified by plating aliquots of the serially diluted
samples on 5% (wt/vol) sheep blood agar plates, incubated overnight at
378C.
Dosing Protocol
Rabbits were randomly dispatched in treatment groups: four groups of
8 animals, received 102 of S. aureus in their right eye. After the clinical
confirmation of the insult of an endophthalmitis (i.e., red ring,
conjunctival edema, bogginess of iris, or loss of red reflex), animals
were treated with linezolid at different intravitreal doses: 1 mg in group
1 (LZD 1), 10 mg in group 2 (LZD 10), and 30 mg in group 3 (LZD 30).
Rabbits of the fourth group (V1) received 1 mg of vancomycin, which
is considered as the treatment of reference of Gram-positive bacterial
endophthalmitis. A control group of 4 rabbits had their right eye
infected, then injected with physiologic saline (balanced salt solution,
BSS; Alcon, Ltd., Fort Worth, TX), 24 hours after the inoculum. This
group constituted the positive control group (BSSþ). The second
control group of 4 animals received a sterile physiologic saline
injection in place of the bacterial inoculum, and then received a BSS
injection at 24 hours. This group was the negative control group (BSS)
(Table 2).
Intravitreal Injections of Antibiotics
Linezolid (Zyvox; Pfizer France, Paris, France) was obtained as pure
titrated powder, and diluted in a sterile solution of BSS, to obtain 1, 10,
and 30 mg of LZD in a volume of 100 lL. Vancomycin (Vancomycine
Sandoz; Sandoz SAS, Levallois-Perret, France) was prepared from an
injectable powder, to get a dose of 1 mg diluted in 100 lL of BSS.
Before each intravitreal injection, rabbits were anesthetized with an
intramuscular injection of a mixture of ketamine (30 mg/kg body
weight; Virbac, Carros, France) and xylazine (Rompun 2%, 4 mg/kg
body weight; Bayer Pharma, Puteaux, France). A drop of oxy-
buprocaine (Oxybuprocaine Faure 1.6 mg/0.4 mL; Novartis Pharma
SAS, Rueil Malmaison, France) was instilled prior to each punction of
the eye. The antibiotic was delivered 24 hours after the bacterial
inoculation, through a 27-gauge needle mounted on a tuberculin
syringe, introduced at 3 mm posterior to the limbus, into the vitreous
cavity, directed toward the center of the eyeball, avoiding the
crystalline lens.
Clinical Investigations
Eyes were observed clinically before and at various time points during
the infection (days 1, 3, 5, and 8 after the bacterial inoculation).
Clinical modifications were assessed in a masked fashion by an
ophthalmologist, according to the criteria of Nussenblatt.19 Briefly, five
increasing levels of severity of damage were scored for the anterior
TABLE 1. Oxacillin, Vancomycin, and Linezolid MICs for the S. aureus
Strain
Strain MICs (mg/L) Susceptibility
Staphylococcus
aureus (ATCC 29737)
Oxacillin > 2 R
Vancomycin ¼ 0.5 S
Linezolid ¼ 2 S
Abbreviations: R, resistant; S, susceptible.
TABLE 2. Animals and Treatment Regimens
Group
Animals
(n)
Intravitreal Injection
(100 lL)
LZD 1 8 1 mg of linezolid
LZD 10 8 10 mg of linezolid
LZD 30 8 30 mg of linezolid
V1 8 1 mg of vancomycin
Control þ (BSSþ) 4 Infected, treated with balanced
salt solution
Control  (BSS) 4 Noninfected, treated with balanced
salt solution
Three different dosages of linezolid were given (groups 1 to 3).
The standard treatment made of 1 mg of vancomycin was given in
group 4. Two control groups were also studied.
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segment and annexes (graded from 0 to 4 points) and five other levels
were scored for the posterior segment (0 to 4 points) observed by
direct ophthalmoscopy (Heine Optotechnik GmbH, Herrsching,
Germany). The sum of these two scores, from 0 point (normal) to 8
points (severely damaged), constituted the ocular inflammation score
of Nussenblatt.
Samples Collection
Fifty to 75 lL of vitreous was aspired with a 25-gauge needle mounted
on a 2-mL syringe, introduced at 3 mm of the limbus, directed toward
the center of the eyeball, cautiously avoiding any bleeding. Vitreous
samples were collected at day 1 to confirm the presence of an
TABLE 3. Inflammation Was Graded in the following Ocular Structures: Cornea, Anterior Chamber, Vitreous, and Retina of Each Studied Eye
Grade of
Damages
in Points
Histologic Parameters
Cornea Anterior Chamber Vitreous Retina
0 No infiltration of inflammatory
cells
Normal No inflammation Normal
1 Partial-thickness infiltration of
inflammatory cells
Partially filled with fibrin; no
inflammatory cells
Inflammatory cells visible; no
focal abscesses
Partially infiltrated and
necrotic; some normal retina
visible
2 Segmental full-thickness
infiltration of inflammatory
cells
Partially filled with fibrin and
inflammatory cells
Partially filled with abscesses
and infiltrate
Totally infiltrated and partially
necrotic; no normal retina
3 Total full-thickness infiltration
of inflammatory cells
Completely filled with fibrin
and inflammatory cells
Completely filled with
infiltrate
Totally necrotic; no retina layer
intact
A score from 0 (normal) to 3 points (severely damaged) was attributed for each structure. The histologic ocular score,20,21 expressed in points
(from 0 to 12), corresponded to the sum of the damage scores of each of the ocular structures.
FIGURE 1. (A) Clinical scores corresponding to the Nussenblatt score just before the treatment (day 1), and at different time points after the
treatment (days 3, 5, 8). Values are means6 SD. Asterisk corresponds to a value of P < 0.05 considered as significant, one-way ANOVA. (B) At day 5,
LZD 1 and the BSSþ groups displayed the highest clinical scores traducing the highest damages of ocular structures. LZD 30 displayed the lower
clinical scores at all endpoints and the difference was significantly different with the BSSþ group (P  0.05, one-way ANOVA, with multiple
comparison test).
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endophthalmitis by a positive culture, and at day 2 to measure the
residual concentrations of antibiotic 24 hours after the intravitreal
administration. Samples were repeated at day 5 and at day 8 to assess
the bacterial growth.
Vitreous Cultures
A 50-lL aliquot was serially 10-fold diluted in 450 lL of sterile 0.9%
(wt/vol) NaCl. A 100-lL volume of each dilution was plated on a 5%
(wt/vol) sheep blood agar plate and incubated overnight at 378C, to be
counted after 24 hours.
Histology
Four animals from each group were euthanized with 5 mL sodium
pentobarbital (Dolethal; Vetoquinol SA, Lure, France) given intrave-
nously and were enucleated after the clinical scoring on day 8. The
globes were fixed in 4% buffered formaldehyde (v/v) for at least 48
hours, embedded in paraffin, and then cut in 5-lm-thick sections. All
eyes were sectioned through the optic nerve and any gross
abnormalities were recorded. Sections were stained with hematoxy-
lin–eosin, before microscopic observation (3400). Histologic slides
were reviewed in a masked fashion by an ophthalmic pathologist and
rated according to a predefined score20,21 (Table 3).
Linezolid Assay
The linezolid concentrations were determined by reverse-phase high-
performance liquid chromatography (HPLC) assay, especially dedicated
to eye tissues.22 The liquid chromatograph consisted of a 125 solvent
delivery module (Beckman Coulter, Fullerton, CA), an injection valve
(Beckman Instruments Inc., San Ramon, CA) with a loop of 20 lL and a
variable-wavelength detector (model 166; Beckman Coulter). Chro-
matograms were processed by a commercial data analysis package (32
Karat Software v. 5.0; Beckman Coulter). Chromatography was
performed on a high-speed analytical column (150 3 4.6 mm ID),
packed with 5-lm-diameter particles (UltrasphereXL-ODS; Beckman
Coulter). The mobile phase consisted of 25 mM ammonium acetate-
acetonitrile (76:24, v/v), adjusted to pH 5 with glacial acetic acid. The
flow rate was set at 1.0 mL/min and the eluent was monitored at 251
nm. The vitreous humor was centrifuged for 10 minutes at 3000g, and
then the supernatant was mixed with an equal volume of acetonitrile in
a 5-mL screw-capped glass tube on a commercial mixer (Vortex mixer;
Vortex Manufacturing Co., Cleveland, OH). The resulting mixture was
FIGURE 2. (A) Mean bacterial counts in the vitreous expressed in log 10 CFU/mL, in control and treated eyes. Values are means 6 SD. Asterisk
corresponds to P  0.05, one-way ANOVA. (B) The multiple comparison test showed a significant decrease in bacterial counts at days 5 and 8, in the
LZD 30 and V1 groups in comparison with the LZD 1 and BSSþ groups (P < 0.05).
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centrifuged again for 10 minutes at 3000g; 20 lL of the aliquot of the
upper aqueous layer was injected into the HPLC column.
Electroretinography
Electroretinograms (ERGs) were recorded according to previously
published procedures.23,24 Five healthy rabbits were dark-adapted
overnight prior to ERG recordings. All further procedures were carried
out under dim red light (k: 650 nm). Anesthesia was induced by
intramuscular injection of ketamine (50 mg/kg, Imalge`ne 1000; Merial,
Lyon, France) and xylazine (10 mg/kg, Rompun 2%; Bayer Pharma,
Leverkusen, Germany). The pupils were dilated with 0.5% tropicamide
(Ciba Vision Ophthalmics, Blagnac, France). After approximately 5
minutes, animals were positioned in a warming plate that maintained a
constant body temperature, and the corneal electrodes were put in
place. The ERG was recorded via corneal electrodes (thin gold wire
with a 4-mm ring end); reference and ground electrodes (silver
needles) were placed on the forehead and tail, respectively. The
recording setup featured a Ganzfeld bowl, an amplifier, and a
computer-based control and recording unit (RETI port/scan 21; Stasche
& Finger GmbH, Roland Consult, Brandenburg, Germany). ERG
responses were recorded from both eyes simultaneously after the
rabbits were placed in the Ganzfeld bowl. Band-pass filter width was 1
to 300 Hz for single-flash and flicker-stimuli recordings, which were
obtained under both dark-adapted (scotopic) and light-adapted
(photopic) conditions. Single-flash stimuli were presented with
increasing intensities, reaching from 103 candelas per second per
m2 (cds/m2) to 10 cds/m2, divided into six steps for scotopic ERG (103
cds/m2, 102 cds/m2, 101 cds/m2, 1 cds/m2, 3 cds/m2, and 10 cds/m2),
and four steps for photopic ERG (33 101 cds/m2, 1 cds/m2, 3 cds/m2,
and 10 cds/m2). Ten to 30 responses were averaged with an
interstimulus interval of 5 seconds (for 103 cds/m2, 102 cds/m2,
101 cds/m2) or 17 seconds (for 33 101 cds/m2, 1 cds/m2, 3 cds/m2,
and 10 cds/m2). Flicker stimuli had an intensity of 3 cds/m2 with
frequencies of 1, 5, 15, and 30 Hz. Light-adaptation was performed
with a background illumination of 25 cd/m2 presented for 3 minutes,
to reach a stable level of the photopic response. The oscillatory
potentials (OPs) were recorded prior to photopic ERG at a stimulus
intensity of 10 cds/m2 and using a band-pass filter width of 200 to 500
Hz.
Immediately after the first ERG recording, right eyes were injected
with 30 mg of LZD (100 lL) and the left eyes, which served as control
eyes, received an intravitreal injection of sterile physiologic salt
solution (100 lL). ERG recordings were renewed 1 day and 14 days
after the intravitreal injections.
Statistical Analysis
All values represent the mean 6 SD for ‡4 eyes per time point assayed
unless otherwise specified. For the histologic score, all values
represent the mean 6 SD for 4 eyes. Descriptive statistics and one-
tailed ANOVA, assuming equal (n ‡ 5) or unequal (n < 5) variance,
were used for statistical comparisons between groups. P  0.05 was
considered significant. A Tukey–Kramer multiple comparisons test was
performed if the value of P was less than 0.05. Statistics were
calculated by using a commercial data analysis package (GraphPad
InStat; GraphPad Software, Inc., San Diego, CA).
RESULTS
Antistaphylococcal Efficacy
All eyes that received a bacterial inoculum developed an acute
endophthalmitis, clinically observed after 24 hours. There was
TABLE 4. Key Pharmacokinetic/Pharmacodynamic (PK/PD) Parame-
ters from the Three Linezolid Groups
Injected Dose of LZD 1 mg 10 mg 30 mg
Cmax (mg/L) 666.6 6,700.6 20,003
C24h (mg/L), n ¼ 4 0.1 1.1 7.2
Vitreous half-life (h) 1.89 1.91 2.09
t > MIC (%) 65.8 92.9 100
AUC24h/MIC (mg/Lh) 3999.5 39,999.6 119,958
Mean vitreous volume of 1.5 6 0.3 mL.
FIGURE 4. Histologic scores expressed in points. LZD 30 displayed the
most conserved ocular anatomical features.
FIGURE 3. Percentage of eyes with viable bacteria from the vitreal taps at the different time points. LZD 10 sterilized half of the eyes at day 5 but a
bacterial regrowth occurred in 2 eyeballs. LZD sterilized all eyes at day 5. At day 8 one regrowth was noticed in both the LZD 30 and the V1 groups.
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no significant difference in the size of the injected bacterial
inoculum at day 0 (P > 0.05). At day 1, just before the
antibiotic intravitreal administration, groups were comparable
in terms of clinical scores (P > 0.05) (Fig. 1) and bacterial
counts (P > 0.05) from the vitreous of eyes infected with S.
aureus (Fig. 2).
A 1 mg intravitreal injection of linezolid appeared to be
ineffective in treating the endophthalmitis: neither the clinical
score (Fig. 1) nor bacterial count in the vitreous (Fig. 2) was
significantly different from those of the BSSþ group (P > 0.05).
In addition, none of the eyes was sterilized at any time point in
this group (Fig. 3).
The 10 mg dose of linezolid produced a mixed effect: at day
5, it reduced the bacterial count compared with the LZD 1 and
the BSSþ group (P < 0.05) and half of the eyes were sterilized
(Fig. 3). However, at day 8 a bacterial regrowth was noticed in
2/8 eyes and the bacterial count in this group was no longer
different from the ones of the LZD 1 and BSSþ groups (P >
0.05) (Fig. 2). Clinical scores of LZD 10 (Fig. 1), which
improved at day 5 compared with those of LZD 1 and BSSþ (P
< 0.001) were no longer different from these groups at day 8
(P > 0.05) (Fig. 1).
The intravitreal Injection of 30 mg of linezolid demonstrat-
ed the most potent antistaphylococcal activity. The clinical
features improved significantly compared with LZ1 and BSSþ
groups at days 5 and 8 (P < 0.001) (Fig. 1). However, there was
no difference in clinical scores with the V1 group. At days 5
and 8, a decrease in the bacterial count of the LZD 30 group
FIGURE 5. Optic microscopy pictures of hematoxylin-eosin–stained rabbit retina slides (x100 and x400). The corresponding treatment groups are
enclosed in brackets. (A) Normal aspect of the retina with an empty vitreous (BSS). (B) Partially infiltrated and necrotic retina, but some layers are
seen (cross) (LZD 10). (C) Totally infiltrated and necrotic retina without any intact retinal layer and with a vitreous filled with inflammatory cells
(LZD 1). (D) Some isolated inflammatory cells are visible in the vitreous (LZD 30). (E) Basophilic focal abscesses are found in the vitreous (asterisk)
(BSSþ). (F) Vitreous completely filled with infiltrate (LZD 1). (G) Normal aspect of the cornea (BSS). (H) Cornea partially infiltrated with
inflammatory cells (LZD 10). (I) Anterior chamber completely filled with fibrin; some inflammatory cells are present (LZD 1). Intravitreal
administration of 1, 10, and 30 mg of LZD (LZD 1, LZD 10, LZD 30, respectively). Administration of the treatment of reference made of 1 mg of
vancomycin (V1). Positive control group (BSSþ) and negative control group (BSS).
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was noticed compared with those of the other groups (P <
0.05), except the V1 group (Fig. 2). At day 5, 8/8 eyes were
sterilized with LZD 30, whereas 7/8 eyes were sterilized with
V1 (Fig. 3). At day 8, a bacterial regrowth was noticed in a
single eye of both the LZD 30 and the V1 groups.
Residual concentrations of linezolid, measured 24 hours
after the intravitreal injection of linezolid, were 0.1 6 0.3, 1.1
6 0.6, and 7 6 1.6 mg/L in the LZD 1, LZD 10, and LZD 30
groups, respectively. The vitreous half-time of linezolid was
calculated by the formula (24 x log 2)/log (Cmax /C24h). In
consequence according to a first-order kinetics elimination, the
linezolid estimated half-time in the vitreous was between 1.9
and 2.1 hours (Table 4).
Histologic Analysis
There was a significant difference in the histologic scores
between groups (P¼ 0.017, Kruskal–Wallis test) (Fig. 4). Eyes
from the LZD 30 and V1 groups possessed intact retinal
architecture, and few inflammatory cells in the vitreous. Eyes
from the LZD 10 group exhibited a mild to moderate
inflammatory response in the anterior segment and the
vitreous. Inflammatory cells and sometimes cocci were
observed throughout the vitreous, but occurred in greatest
numbers at vitreous interfaces and on the posterior surface of
the ciliary body. Retinal architecture was disrupted, with
retinal detachment, photoreceptor layer folding, and inflam-
matory cells located within the retinal layers. However, some
normal retinal tissue was seen. Inflammatory cells were
observed migrating from the vitreous into the retina (Fig. 5).
In general, these eyes were less inflamed than those of the LZD
1 group and from the BSSþ group. The LZD 1 and BSSþ groups
exhibited severe inflammation in all parts of the eye.
Inflammatory cells migrated in more significant numbers into
the corneal periphery, forming a corneal ring abscess.
Inflammatory cells, fibrin, and sometimes erythrocytes filled
the anterior segment. Retinal structures were indistinguishable
and the posterior chamber was filled with inflammatory cells
and fibrin.
Functional Analysis
The scotopic single-flash ERG a- and b-wave amplitudes and
implicit times are presented in Table 5. The eyes treated with
LZD at a dose of 30 mg did not display any modification in the
ERG a-wave and b-wave amplitudes and latencies when
compared with contralateral eyes under both dark- and light-
adapted conditions. The ERG traces had a conventional aspect
(Fig. 6). In scotopic conditions, a pure rod response was visible
at 10 mcds/m2, whereas a mixed rod/cone response was
observed at 10,000 mcds/m2. The photopic cone ERG at
10,000 mcds/m2 was a standard cone response characterized
by a pyramidal aspect and the presence of low-frequency
oscillatory potentials on its top. When stimulated at 30 Hz,
retinas treated with LZD displayed well-individualized respons-
es comparable to those of contralateral eyes under both
scotopic and photopic conditions. The isolated oscillatory
potentials did not reveal any difference between LZD-treated
and contralateral eyes.
TABLE 5. ERG a- and b-Wave Amplitudes and Latencies Recorded in Scotopic and Photopic Conditions Prior to and after LZD Treatment
Stimulus
Intensity
Before Treatment 1 Day Post-treatment 14 Days Post-treatment
Contralateral LZD-Treated Contralateral LZD-Treated Contralateral LZD-Treated
Scotopic a-wave
Amplitude (lV) 1,000 mcds/m2 24.2 6 5.4 30.7 6 5.4 31.2 6 10.9 28.4 6 7.6 33.3 6 6.9 28.1 6 3.8
3,000 mcds/m2 36.6 6 21.8 35.6 6 4.8 39.9 6 10.4 37.1 6 11.0 41.4 6 8.9 40.5 6 6.7
10,000 mcds/m2 40.2 6 7.3 45.0 6 7.8 47.8 6 15.6 43.6 6 12.1 44.0 6 4.7 44.0 6 8.1
Latency (ms) 1,000 mcds/m2 14.0 6 1.4 13.6 6 0.8 14.8 6 0.4 14.4 6 0.8 14.6 6 0.8 14.8 6 0.8
3,000 mcds/m2 11.4 6 1.6 12.0 6 3.0 12.8 6 1.1 12.0 6 1.0 12.8 6 1.1 12.0 6 1.5
10,000 mcds/m2 10.4 6 0.5 11.4 6 11.6 11.6 6 0.8 11.0 6 0.7 11.6 6 1.5 11.6 6 1.5
Scotopic b-wave
Amplitude (lV) 1 mcds/m2 9.6 6 7.4 9.8 6 4.9 7.6 6 2.7 11.9 6 4.6 9.8 6 5.2 11.0 6 5.1
10 mcds/m2 65.3 6 24.6 59.5 6 23.4 60.3 6 7.2 62.3 6 2.6 60.5 6 10.5 69.5 6 12.7
100 mcds/m2 86.3 6 30.1 84.8 6 21.4 83.3 6 8.6 81.5 6 7.8 80.4 6 8.4 79.2 6 13.4
1,000 mcds/m2 100.5 6 38.5 99.9 6 41.5 102.1 6 22.5 100.2 6 15.4 101.7 6 30.5 105.1 6 11.8
3,000 mcds/m2 99.5 6 29.5 107. 6 38.8 101.7 6 9.5 104.6 6 8.9 102.1 6 14.1 105.1 6 15.9
10,000 mcds/m2 108.3 6 39.8 104.8 6 19.2 99.5 6 9.9 109.2 6 6.9 117.3 6 16.8 108.1 6 12.4
Latency (ms) 1 mcds/m2 61.6 6 1.5 63.2 6 2.3 62.2 6 5.0 61.0 6 4.4 74.6 6 16.4 62.0 6 6.9
10 mcds/m2 55.4 6 4.5 55.2 6 6.0 53.6 6 3.3 55.8 6 4.2 55.2 6 4.9 56.6 6 4.3
100 mcds/m2 37.2 6 2.2 36.0 6 1.5 36.4 6 1.9 37.0 6 1.0 36.8 6 1.4 38.2 6 3.9
1,000 mcds/m2 34.8 6 2.3 34.8 6 1.9 35.4 6 1.5 34.6 6 1.8 36.2 6 1.7 35.2 6 5.7
3,000 mcds/m2 34.2 6 3.4 34.8 6 4.1 34.4 6 1.5 34.2 6 3.1 33.4 6 0.8 34.8 6 1.7
10,000 mcds/m2 33.4 6 2.0 33.6 6 2.1 33.2 6 1.4 33.8 6 1.7 33.6 6 0.5 34.0 6 7.9
Photopic b-wave
Amplitude (lV) 300 mcds/m2 12.1 6 15.2 11.4 6 15.6 11.3 6 3.3 14.5 6 7.7 12.9 6 7.0 13.0 6 4.9
1,000 mcds/m2 22.3 6 12.4 33.8 6 10.4 25.1 6 3.9 21.7 6 7.4 22.8 6 6.2 21.1 6 5.9
3,000 mcds/m2 61.0 6 21.7 53.8 6 15.9 53.6 6 6.1 55.8 6 14.7 55.7 6 17.1 67.1 6 25.5
10,000 mcds/m2 59.5 6 10.3 56.2 6 13.0 60.9 6 4.6 60.7 6 12.2 60.3 6 12.6 65.0 6 23.1
Latency (ms) 300 mcds/m2 35.2 6 7.4 37.2 6 8.1 34.8 6 2.2 34.6 6 3.7 32.8 6 1.3 34.0 6 3.1
1,000 mcds/m2 27.6 6 4.7 28.4 6 6.1 28.2 6 2.2 29.4 6 3.7 29.8 6 2.9 29.8 6 0.8
3,000 mcds/m2 29.0 6 1.7 29.8 6 1.4 29.0 6 2.0 29.4 6 3.2 29.0 6 1.5 29.6 6 2.0
10,000 mcds/m2 23.2 6 4.4 23.8 6 4.0 23.2 6 1.7 22.8 6 1.3 24.8 6 4.0 23.8 6 1.3
Values are means 6 SD; n¼ 5.
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DISCUSSION
Linezolid remains a potent anti-Gram-positive antibiotic. The
linezolid surveillance network25 confirmed that LZD retained
excellent activity against monitored Gram-positive pathogens
at a level of more than 99.6%.26 A study of the antibiotic
susceptibility in bacteria isolated from human endophthalmitis
also showed a linezolid susceptibility in 100% of coagulase-
negative Staphylococcus27 and S. aureus. Therefore, linezolid
was recently suggested as an alternative in the treatment of
Gram-positive endophthalmitis.14,16,17 Previous pharmacoki-
netic studies have focused on the intraocular concentrations
obtained by the systemic route, and it appeared that the
maximal concentrations of linezolid after systemic administra-
tion were 6.8 mg/L in the aqueous humor and 5.7 mg/L in the
vitreous.14,16,17 These concentrations were above the minimal
inhibitory concentrations (MICs) of most causative bacteria
(MIC90¼2 mg/L25) and it was suggested that these levels could
be sufficient to treat the Gram-positive–related endophthalmi-
tis. However, there are no data available on the levels obtained
after direct vitreal administration, which remains the best route
of administration of antibiotics in this condition. Indeed, it is
important to consider that the pharmacokinetic requirements
for efficacy in bacterial endophthalmitis are more stringent
compared with those for other tissues such as lungs or the skin
because of the presence of a blood–ocular barrier. The best
route to treat bacterial endophthalmitis remains the intravitreal
route, because it shunts the blood–ocular barrier that limits the
ocular penetration of antibiotics from the blood stream,
providing intravitreal levels of antibiotics higher than those
obtained after a systemic administration for protracted periods
of time.4
Vitreous concentrations of LZD obtained by the vitreal
route in this experimental model are considered high
compared with the concentrations obtained in the serum after
systemic administration. However, the failure of the 1 and 10
mg intravitreal LZD doses in sterilizing the staphylococcal
endophthalmitis was surprising since the peak antibiotic levels
(Cmax) were in all the groups several dilutions greater than the
MIC for linezolid of the inoculated S. aureus (MIC ¼ 2 mg/L)
(Table 4). The failure to sterilize the eye could be partially
explained by the fact that linezolid, which is considered as a
time-dependent antibiotic,28 displayed a very short half-life in
the vitreous. Indeed, its half-life in the inflamed eye was around
2 hours when vancomycin displays a half-time of more than 48
hours in the same conditions.29 This rapid clearance of
linezolid from the vitreous could be related to the severe
ocular inflammation associated with bacterial endophthalmitis
that enhances the elimination of the drug from the ocular
structures as it was previously demonstrated for other
antibiotics (i.e., gentamicin30 or vancomycin29,31).
Pharmacodynamic parameters determining the efficacy of
linezolid against S. aureus in the eye are not known. Most data
on linezolid pharmacodynamics are based on serum concen-
trations and it is admitted that the AUC24/MIC ratio
32 and t >
MIC33 are the most suitable parameters to predict the
antistaphylococcal effect of linezolid. In our experimental
model of endophthalmitis, AUC24/MIC did not appear to be
predictive of antibacterial efficacy, since high ratios reached in
the 1 and 10 mg LZD groups (respectively 3999.5 and 39,999.6
FIGURE 6. Time course of functional responses of rabbit eyes treated or not with LZD at a dose of 30 mg. The representative ERG traces did not
show any difference in aspect between treated (gray traces) and contralateral (black traces) eyes in scotopic and photopic conditions after a single-
flash stimulation or flicker stimuli.
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mg/Lh) were not sufficient to provide a satisfactory bacteri-
cidal activity. Increasing doses of linezolid improved the
bactericidal efficacy of linezolid in the eye. According to
clinical, bacterial, and histologic criteria, the 30 mg of linezolid
was bactericidal and was at least as effective as the injection of
the reference treatment, vancomycin, in curing the endoph-
thalmitis. At this dose, linezolid was also superior to other
regimens in preserving the architecture of the ocular
structures, especially the retinal structure. Such a concentra-
tion-dependent killing of staphylococci exposed to linezolid
has been already reported in an in vitro model.32 However,
even if the gross anatomy was found to be intact, there are no
data available on the toxicity of such doses of intravitreal
linezolid on the retinal function. A study of the visual function,
tested by electroretinography, after intravitreal injection of
linezolid in the eyes of rabbits, was performed only at low
doses of linezolid (up to 300 lg/0.1 mL).34 It appeared that
linezolid was well tolerated at these doses. It is not known if
higher doses delivered in the vitreous could trigger visual
dysfunction such as optic neuropathies that have been
described in prolonged oral administration of linezolid.35
In our study, a 30 mg dose of linezolid appeared to be safe
for the retinal function, even 2 weeks after the intravitreal
injection. Even if numerous ocular pharmacokinetic/pharma-
cokinetic (PK/PD) studies are conducted on rabbits because of
the anatomic characteristics of the rabbit eye (i.e., globe size
and aqueous humor turnover rate comparable to those of
human eyes), caution must be taken before extrapolating these
results to humans. One of the limitations of this study is the
repeated punctures of the eyeball that could result in relative
dilution of the antibiotic in the newly secreted aqueous humor
and a breach in the blood–ocular barrier. However, the same
procedure was performed in the vancomycin group, and it is
likely that dilution occurred in the same proportion in both
groups. To predict more accurately the parameter predictive of
antibacterial efficacy, the relationship of the 24-hour ocular
concentrations to the intensity of the antimicrobial effect
should be explored in a dedicated study. These results
emphasize the diversity of factors involved in antibacterial
activity in vivo and stress the importance of animal models in
complement to the in vitro spectrum of the antibiotic.
In conclusion, this study demonstrates the first evidence of
the effectiveness of linezolid for the treatment of experimental
staphylococcal endophthalmitis. High intravitreal levels are
needed to ensure an acceptable bactericidal effect. Such
intravitreal doses of linezolid appeared to be safe for the retinal
function.
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